Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a regenerative medicine and advanced wound care company whose activities generate frequent news across clinical, regulatory, financial, and legal fronts. The company develops and markets placental tissue–based allografts and other biomaterial products used in chronic and hard-to-heal wounds, burn care, and selected surgical applications, and it regularly updates investors and clinicians on developments affecting these businesses.
News about MiMedx often includes announcements of new product launches and portfolio expansions, such as the introduction of EPIXPRESS, a lyophilized human placental-based allograft, and the exclusive U.S. distribution agreement for RegenKit Wound Gel. The company also highlights clinical and scientific milestones, including peer-reviewed publications on Purion processed human amniotic membrane allografts and interim results from randomized controlled trials like the CAMPAIGN study evaluating EPIEFFECT in nonhealing diabetic foot ulcers.
Investors following MDXG can expect regular earnings releases, conference call details, and commentary on reimbursement policy changes, particularly regarding Medicare rules for skin substitutes and advanced wound care products. MiMedx uses press releases to discuss how reimbursement reforms may affect its market and to describe its operational and commercial positioning.
In addition, MiMedx appears in news related to legal and regulatory matters, including litigation with former employees and references to FDA communications on specific products. Coverage may also include the company’s participation in investor conferences and clinical meetings such as the Symposium on Advanced Wound Care. For those tracking MDXG, this news stream provides insight into product performance, scientific evidence, regulatory context, and corporate strategy over time.
Marietta, Ga. — MiMedx Group (Nasdaq: MDXG) announced its participation in upcoming virtual investor conferences. CEO Timothy R. Wright, CFO Peter M. Carlson, and CCO Rohit Kashyap will engage in fireside chats at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 3:30 PM ET, and the Canaccord Genuity MedTech Forum on November 18, 2021, at 9:30 AM ET. Webcasts will be available via the company’s website. MiMedx specializes in regenerative medicine utilizing amniotic tissue for wound care and musculoskeletal conditions.
MIMEDX announced two peer-reviewed studies on micronized dehydrated human amnion chorion membrane (mdHACM) for treating osteoarthritis and tendinopathy. The studies reveal mdHACM's potential to regulate inflammatory processes and enhance tissue repair. The first study, published in Osteoarthritis and Cartilage Open, highlights mdHACM's chondroprotective effects by inhibiting key signaling pathways in chondrocytes. The second study in the Journal of Biomedical Materials Research, Part B, shows mdHACM diminishes inflammation and promotes healing in chronic tendon injuries, suggesting its role in regenerative medicine.
MiMedx Group, Inc. (Nasdaq: MDXG) will announce its third-quarter financial results for the period ending September 30, 2021, on November 2, 2021, after market close. A webcast and conference call are scheduled for November 3, 2021, at 8:30 AM ET to discuss these results. MiMedx specializes in regenerative medicine, particularly through the use of amniotic tissue. The company has supplied over two million allografts, focusing on treating acute and chronic non-healing wounds while developing a pipeline for degenerative musculoskeletal conditions.
Marietta, Ga. – MiMedx Group, Inc. (Nasdaq: MDXG) announced a virtual Investor Day on December 7, 2021, at 9:00 a.m. ET. The event will showcase the Company’s late-stage pipeline in musculoskeletal conditions and its advanced wound care business. Further registration details will be shared soon. A live webcast is accessible via the Company’s Investors section at www.mimedx.com, with a replay available post-event. MiMedx specializes in amniotic tissue for regenerative medicine, addressing severe non-healing wounds and musculoskeletal pain.
Net Health announced a partnership with MiMedx Group, Inc. (Nasdaq: MDXG) to enhance the insurance verification process for MIMEDX's tissue-based products. The integration of MIMEDX into Net Health's Wound Care software enables hospital and outpatient providers to submit electronic insurance verification forms efficiently. This collaboration aims to reduce administrative burdens on clinicians and expedite insurance approvals. MIMEDX's EPIFIX® product is covered by all national commercial payors, further emphasizing the significance of this partnership in improving patient access to advanced wound care solutions.
MIMEDX announced interim results from its Phase 2B Knee Osteoarthritis (KOA) trial and Phase 3 Plantar Fasciitis (PF) trial. The KOA trial, involving 446 patients, did not meet primary endpoints but showed varied efficacy signals among cohorts, prompting plans for Phase 3 confirmatory studies. The PF trial also failed to meet its primary endpoint, leading to the decision against a Biologics License Application (BLA) at this time. Both trials demonstrated safety with no significant adverse events. MIMEDX intends to consult with the FDA regarding future study directions.
MiMedx Group (Nasdaq: MDXG) has announced the effective shelf registration statement on Form S-3 with the SEC, allowing the sale of up to $350 million in various securities over the next three years. Details regarding future offerings will be disclosed at the time of such offerings. The company intends to announce top-line results from its clinical trials involving micronized dehydrated human amnion chorion membrane (mdHACM) for knee osteoarthritis and plantar fasciitis later this summer. Investors are cautioned to consider potential risks and uncertainties associated with the forward-looking statements.
Marietta, GA, September 7, 2021 - MiMedx Group (Nasdaq: MDXG) announced that CEO Timothy R. Wright, CFO Peter M. Carlson, and Executive VP Robert B. Stein will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be accessible on the Company’s website starting September 13 at 7:00 AM ET for 90 days. MiMedx is recognized for its innovative use of amniotic tissue in regenerative medicine, focusing on wound care and musculoskeletal conditions, having supplied over two million allografts to date.
Mariietta, Ga. (Aug. 27, 2021) - MiMedx Group, Inc. (MDXG) filed a Form S-3 shelf registration with the SEC, allowing the sale of up to $350 million in securities over three years. This filing is seen as a positive step towards financial stability and governance. CFO Peter M. Carlson emphasized that while there are no immediate plans to issue securities, this provides flexibility for future growth initiatives. The registration will be effective for three years upon SEC approval. Caution is noted regarding pending Phase 2B and Phase 3 clinical trial results for knee osteoarthritis and plantar fasciitis.
MiMedx Group, Inc. (MDXG) announced the publication of a pivotal study in the Journal of Wound Care demonstrating that advanced treatment (AT) for lower extremity diabetic ulcers (LEDUs) significantly reduces major and minor amputations by 42% compared to standard care. The research utilized Medicare data from 2015 to 2018, highlighting a decrease in hospital readmissions and emergency department visits. With over 3 million Americans affected by diabetic foot ulcers, this study emphasizes the financial and health benefits of timely and effective treatment approaches.